Containing Solid Synthetic Polymers Patents (Class 424/497)
-
Publication number: 20130243871Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell McMAHEN
-
Publication number: 20130243876Abstract: The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).Type: ApplicationFiled: November 23, 2011Publication date: September 19, 2013Applicant: Georgia Tech Research CorporationInventors: John McDonald, Nathan John Bowen, LiJuan Wang
-
Publication number: 20130243689Abstract: Disclosed are multi-compartmental nanoparticulate systems for imaging as well as the diagnosis, monitoring, and treatment of inflammation and/or disease. These multicompartmental nanoparticulate systems can be used to target specific cells or ceullular structures. Furthermore, these systems are capable of simultaneous delivery of hydrophilic and lipophilic compositions. Finally, these systems also allow for temporal control of drug delivery.Type: ApplicationFiled: March 24, 2011Publication date: September 19, 2013Inventors: Mansoor M. Amiji, Mayur Kalariya, Shardool Jain, Husain Attarwala
-
Publication number: 20130243868Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.Type: ApplicationFiled: February 26, 2013Publication date: September 19, 2013Applicant: Avant Garde Therapeutics and Technologies LLCInventors: Leo RUBIN, Shaker Mousa
-
Patent number: 8535799Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.Type: GrantFiled: February 27, 2007Date of Patent: September 17, 2013Assignee: Veloxis Pharmaceuticals A/SInventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
-
Publication number: 20130236543Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Masanori ITO, Kenji EGUSA, Kyle KLEINBECK, Roman MESSERSCHMID, Peter SCHNEIDER, Venkata VOLETI
-
Publication number: 20130236540Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: March 22, 2013Publication date: September 12, 2013Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
-
Publication number: 20130236554Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell McMahen
-
Publication number: 20130236555Abstract: The present invention relates to organic polymeric photon up-conversion nanoparticles for biological applications, such as labeling and/or detection of cells, biological (macro-) molecules or other analytes, as well as for sensing temperature, pressure, oxygen and other substances that influence the up-conversion process. It further relates to organic photon up-conversion nanoparticles for singlet oxygen generation and the treatment of diseases, such as cancer.Type: ApplicationFiled: March 28, 2013Publication date: September 12, 2013Applicant: SONY CORPORATIONInventors: Tzenka MITEVA, Gerda Fuhrmann, Gabriele Nelles, Vladimir Yakutkin, Stanislav Balouchev
-
Publication number: 20130236556Abstract: The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues.Type: ApplicationFiled: March 29, 2013Publication date: September 12, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Samuel K. Lai, Ming Yang, Ying-Ying Wang, Olcay Mert, Laura Ensign, Justin Hanes, Jie Fu
-
Patent number: 8529955Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: September 10, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Publication number: 20130230588Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Applicant: TEMREL LIMITEDInventors: Christopher J. SPEIRS, Peter MOIR, Richard WILLIAMS, Michael CLARK
-
Publication number: 20130230587Abstract: Sustained release compositions comprising plurality of sustained release beads are disclosed. Particularly the sustained release beads comprise coated drug-resin complexes comprising drug-resin complexes of at least one active agent and at least one ion-exchange resin; coated with at least one release modifier.Type: ApplicationFiled: November 10, 2010Publication date: September 5, 2013Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anikumar Surendrakumar Gandhi
-
Publication number: 20130230596Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Applicant: Elite Laboratories, Inc.Inventor: Atul M. Mehta
-
Patent number: 8524260Abstract: The invention consists of a method for manufacturing an aqueous formulation containing at least one oil, and comprising the steps of mixing at least one associative polymer, one oil, and water, encapsulating the oil by increasing the pH to a value greater than 8, potentially precipitating the mixture by reducing the pH to a value less than 6, and potentially isolating the resulting particles by removing the water. The aqueous formulations, as with the aqueous dispersions, and the resulting solid particles constitute other objects of the invention.Type: GrantFiled: December 3, 2008Date of Patent: September 3, 2013Assignee: Coatex S.A.S.Inventors: Jean Moro, David Platel, Jean-Marc Suau, Olivier Guerret
-
Publication number: 20130224295Abstract: It is an object of the present invention to provide a powder, a granule, an orally-disintegrating tablet, and the like that contain a drug causing bitterness, and that can suppress the bitterness in the mouth and improve solubility thereof in the stomach. The present invention provides a drug-containing granule comprising (a) a core particle that contains a drug causing bitterness, and (b) a masking coating that coats the core particle, wherein the masking coating contains: at least one polymer selected from methacrylic acid copolymer S, methacrylic acid copolymer L, methacrylic acid-ethyl acrylate copolymer, ethyl acrylate-methyl methacrylate copolymer, and ethyl acrylate-methyl methacrylate-ethyl ammonium trimethyl chloride methacrylate copolymer; and at least one diluent selected from D-mannitol, lactose, trehalose, xylitol, maltitol, and erythritol, an orally-disintegrating tablet comprising the drug-containing granule, and the like.Type: ApplicationFiled: April 8, 2011Publication date: August 29, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yuji Miyamoto, Takuya Tokuda, Motohiro Ota, Yasuhiro Ishikawa
-
Patent number: 8518449Abstract: An improved method for fixedly binding particles of a solid, heat absorbing material or additive, especially polymer additives, to the surface of prepolymer and/or polymer particles.Type: GrantFiled: August 24, 2007Date of Patent: August 27, 2013Assignee: Sciessent LLCInventors: Jeffrey A. Trogolo, Edward K. Welch, II
-
Patent number: 8519051Abstract: The present invention provides a block copolymer for a drug conjugate which comprises a water-soluble polymer region consisting of polyethylene glycol and a polyamino acid region having a hydrazide group and a hydrophobic group in the side chain.Type: GrantFiled: October 19, 2007Date of Patent: August 27, 2013Assignee: Nanocarrier Co., Ltd.Inventors: IuIian Bobe, Naoya Shibata, Hiroyuki Saito, Mitsunori Harada
-
Publication number: 20130216617Abstract: The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers.Type: ApplicationFiled: June 28, 2011Publication date: August 22, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Manohar Vishwanath Lalge, Vaibhav Panditrao Deshmukh
-
Patent number: 8512757Abstract: The invention provides a block copolymer comprising at least a first block and a second block. The first block comprises a plurality of temperature-sensitive monomeric units, a plurality of hydrophilic monomeric units and a plurality of targeting monomeric units, and the second block comprises a plurality of hydrophobic monomeric units. The second block comprises at least one pH-sensitive moiety.Type: GrantFiled: July 5, 2006Date of Patent: August 20, 2013Assignee: Agency for Science, Techology and ResearchInventors: Yi-Yan Yang, Shao-Qiong Liu
-
Patent number: 8513206Abstract: The present invention relates to a novel crosslinked polyethylenimine (PEI) nanoparticle based nucleic acid transfection agent wherein the crosslinker is having carbon chain in the range of C2 to C8, ranging between 3.27-19.8%, having the size of nanoparticle ranging between 20-600 nm and zeta potential ranging from +5 to 50 mV.Type: GrantFiled: July 29, 2008Date of Patent: August 20, 2013Assignee: Council of Scientific and Industrial ResearchInventors: Kailash Chand Gupta, Pradeep Kumar, Archana Shami, Atul Pathak
-
Publication number: 20130209568Abstract: The invention is directed to biodegradable, thermoplastic, phase separated segmented multi-block copolymers. The copolymers of the present invention find use in various biomedical applications as well as in pharmaceutical applications. Provided is a composition for the controlled release of at least one biologically active polypeptide to a host, comprising the at least one biologically active polypeptide encapsulated in a matrix comprising at least one phase separated, thermoplastic multi-block copolymer, the copolymer being characterized in that (i) it comprises at least two hydrolysable segments chosen from prepolymer (A) and prepolymer (B), prepolymer (A) having a Tg lower than 37° C. and prepolymer (B) having a Tm of 40° C.-100° C. under physiological conditions; (ii) the segments being linked by a multifunctional chain-extender; (iii) the segments are randomly distributed over the polymer chain; and (iv) prepolymer (A) contains a segment that is derived from a water soluble polymer.Type: ApplicationFiled: July 8, 2011Publication date: August 15, 2013Applicant: INNOCORE TECHNOLOGIES B.V.Inventors: Rob Steendam, Theodorus Adrianus Cornelius Flipsen, Christine Hiemstra, Johan Zuidema
-
Publication number: 20130209539Abstract: It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation.Type: ApplicationFiled: February 13, 2013Publication date: August 15, 2013Applicant: CHEMO RESEARCH, S.L.Inventor: CHEMO RESEARCH, S.L.
-
Publication number: 20130209567Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once—daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.Type: ApplicationFiled: August 9, 2012Publication date: August 15, 2013Applicant: Aptalis Pharamtech, Inc.Inventors: Gopi M. Venkatesh, James M. Clevenger
-
Patent number: 8506981Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: April 23, 2013Date of Patent: August 13, 2013Assignee: Synergy Biomedical LLPInventor: Mark D. Borden
-
Publication number: 20130202712Abstract: The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.Type: ApplicationFiled: March 2, 2011Publication date: August 8, 2013Applicant: VINDICO NANOBIO TECHNOLOGY, INC.Inventors: Eric M. Ostertag, Paul C. Tumeh, P. Peter Ghoroghchian
-
Publication number: 20130202688Abstract: The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: May 3, 2011Publication date: August 8, 2013Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Hemant Manilal Mamania
-
Publication number: 20130195755Abstract: The field of the present invention relates to the stabilisation of nanoparticles in aqueous dispersion and, in particular, the stabilisation of nanoparticles by encapsulating the nanoparticles in a micellular combination. The field of the present invention further relates to a micellular combination of nanoparticles and a method of manufacture of the micellular combination and uses thereof. In a first aspect the present disclosure teaches a micellular combination that allows the stable dispersion of nanoparticles into aqueous environment. The micellular combination comprises at least one nanoparticle in a core of the micellular combination. A plurality of surfactants is co-assembled with a plurality of hydrophobic ligands on the surface of the nanoparticle in such a way that the hydrophilic part of the surfactant forms a hydrophilic shell around the core of the micellular combination.Type: ApplicationFiled: June 28, 2011Publication date: August 1, 2013Applicant: CENTRUM FUR ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBHInventors: Elmar Poselt, Hauke Kloust, Horst Weller, Christian Schmidtke, Christian Fuhrmann, Sascha Kappen, Werner Pauer, Hans-Ulrich Moritz
-
Publication number: 20130195988Abstract: A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 ?m. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: Shanghai Cancer InstituteInventor: Shanghai Cancer Institute
-
Publication number: 20130195987Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.Type: ApplicationFiled: December 19, 2012Publication date: August 1, 2013Applicant: INTEZYNE TECHNOLOGIES, INC.Inventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
-
Publication number: 20130195974Abstract: The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5 to 5.5. A process for preparing said composition is also claimed.Type: ApplicationFiled: May 12, 2011Publication date: August 1, 2013Inventors: Péter Hajnal, Péter Szegõ, István Nándor Antal, Judit Dredán, Imre Klebovich, Miléna Bea Lengyel
-
Patent number: 8497229Abstract: A granular agrochemical composition is disclosed including a granular core material having a water soluble portion with a first coating layer applied on the surface of the core material and a second coating layer applied on the surface of the first coating layer. The first coating layer includes a wax composition having a biologically active ingredient incorporated therein and the second coating layer includes a polymeric composition. The granular agrochemical composition exhibits a controlled rate of release of the biologically active ingredient therefrom over a period greater than about 30 days from the date of initial exposure of the granular composition to moisture whereby essentially all of the biologically active ingredient incorporated in the wax material of the first coating layer is released from the granular composition before the water soluble portion of the granular core material is released from the granular composition.Type: GrantFiled: January 18, 2011Date of Patent: July 30, 2013Assignee: Everris International B.V.Inventors: Lonneke Jacoba van Boxtel-Verhoeven, Johannes Gijsbertus Antonius Terlingen, Petra Leonarda Hendrica Lunde-Vannuys
-
Publication number: 20130189347Abstract: A disease treatment drug having high pharmacological effects and no side effects is provided, the disease treatment drug being capable of intensively delivering an iron or manganese porphyrin complex capable of removing active oxygen to abnormal tissue within a living body, and effectively removing the active oxygen within the abnormal tissue. The disease treatment drug contains an iron or manganese porphyrin complex nanocapsule housing an iron or manganese porphyrin complex within a nanosized capsule. In the disease treatment drug, disease of abnormal tissue having a high concentration of active oxygen can be treated by the iron or manganese porphyrin complex delivered into the abnormal tissue as a result of the nanocapsule, without affecting normal tissue having a low concentration of active oxygen, and side effects can be suppressed.Type: ApplicationFiled: January 29, 2013Publication date: July 25, 2013Inventors: Makoto YUASA, Risa YUKI
-
Publication number: 20130189369Abstract: A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye.Type: ApplicationFiled: January 22, 2013Publication date: July 25, 2013Applicant: ALLERGAN, INCInventor: ALLERGAN, INC
-
Publication number: 20130189366Abstract: Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed.Type: ApplicationFiled: January 24, 2013Publication date: July 25, 2013Applicants: Brown University, The United States Government as Represented by the Department of Veterans AffairsInventors: The United States Government as Represented by the Department of Veterans Affairs, Brown University
-
Publication number: 20130189368Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.Type: ApplicationFiled: June 1, 2011Publication date: July 25, 2013Applicant: UNIVERSIDADE FEDERAL DE OURO PRETOInventors: Vanessa Carla Furtado Mosqueira, Raquel Silva Araújo, Humberto de Mello Brandão
-
Publication number: 20130177615Abstract: The present invention relates to topical compositions containing solid particles that are stabilized via encapsulation into a cross-linked silicone matrix. The stabilized particles possess an electrical potential sufficient to prevent the particles from penetrating into the skin. The particles can readily be used either alone or in combination with other skin care actives to form topical compositions with improved stability and performance.Type: ApplicationFiled: July 9, 2012Publication date: July 11, 2013Inventor: Wilson A. Lee
-
Publication number: 20130177652Abstract: The invention relates to pharmaceutical oral dosage forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran etexilate) and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate.Type: ApplicationFiled: July 1, 2011Publication date: July 11, 2013Applicant: KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTOInventor: Vesna Kroselj
-
Patent number: 8475813Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: July 2, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20130164381Abstract: The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T2 relaxation times.Type: ApplicationFiled: January 28, 2013Publication date: June 27, 2013Applicant: SOUTHWEST RESEARCH INSTITUTEInventor: Southwest Research Institute
-
Publication number: 20130156859Abstract: An immunogenic composition includes as effective ingredients: an immunogenic micro-particle composed of an antigen-adjuvant microparticle complex wherein an antigen(s) is/are encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydro-phobic segment(s) is/are poly(hydroxy acid); and a surfactant encapsulated in the immunogenic microparticle.Type: ApplicationFiled: August 25, 2011Publication date: June 20, 2013Applicant: Toray Industries, IncInventors: Yoichiro Koshi, Reiji Nishio, Yoshinori Kakizawa
-
Publication number: 20130156858Abstract: A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines.Type: ApplicationFiled: May 30, 2011Publication date: June 20, 2013Applicant: RPH Pharmaceuticals ABInventors: Per Wikström, Tobias Bramer, Lilyan Yachoh
-
Patent number: 8465776Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.Type: GrantFiled: July 31, 2007Date of Patent: June 18, 2013Assignee: EthypharmInventor: Didier Hoarau
-
Patent number: 8465777Abstract: The invention includes a core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles of a release-regulating polymer. The shell may be substantially impervious but the release-regulating polymer may become suitable to allow diffusion through it when activated. The core may include a buffer region between the shell and the API-containing portion of the core. The dosage form may include multiple units. The dosage form of the invention is capable of providing a release profile whose time scale can be adjusted by adjusting powder composition, and which may be approximately zero-order release. The invention further includes methods of manufacturing such a dosage form, such as three-dimensional printing.Type: GrantFiled: November 29, 2011Date of Patent: June 18, 2013Assignee: The Massachusetts Institute of TechnologyInventors: Chen-Chao Wang, Jaedeok Yoo, Esteban Bornancini, Willie J Roach, Monica Tejwani
-
Publication number: 20130149361Abstract: Disclosed is a particle, compositions having the particle, and methods of using the particle or composition, that includes a core having an active ingredient, a coating surrounding the core, and pink tourmaline that is included in the core and/or in the coating.Type: ApplicationFiled: December 13, 2012Publication date: June 13, 2013Applicant: MARY KAY INC.Inventor: Mary Kay Inc.
-
Publication number: 20130142880Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.Type: ApplicationFiled: August 2, 2011Publication date: June 6, 2013Applicant: SOFAR SPAInventor: Carla Labruzzo
-
Publication number: 20130137976Abstract: The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.Type: ApplicationFiled: November 17, 2011Publication date: May 30, 2013Inventors: William L. Neumann, Richard B. Dorshow, John N. Freskos, Karen L. Wooley, Nam S. Lee, Lily Nun Lin, Guorong Sun
-
Publication number: 20130136798Abstract: A controlled release parenteral formulation for treatment of pain and inflammation is provided. The formulation includes an effective amount of: one or more active drug moiety. The drug moiety is selected from a group comprising aceclofenac or diclofenac or a combination thereof; One or more solvent moiety selected from a group comprising one or more of ethyl acetate, triacetin, di methyl iso sorbide, DMA, DMSO, PEG, PVP, PVA, Span 80, DCM, Benzyl alcohol, acetone or a combination thereof. The formulation, upon administration, has a release profile including an immediate burst release and the burst release is followed by a slow release of at least 18 to 24 hrs. The immediate burst release and the slow release of the drug moiety remains within the therapeutic window of the drug moiety.Type: ApplicationFiled: January 5, 2012Publication date: May 30, 2013Inventor: Manu Chaudhary
-
Patent number: 8450380Abstract: The invention pertains to a new method for formulating pharmaceutical active ingredients in such a way as to protect them when ingested orally, and to allow for the controlling of the release of the active ingredient in the intestine. It relies upon the use of thickening acrylic emulsions with a pH greater than 5, containing hydrophobic groups, in order to encapsulate the pharmaceutical active ingredients for the purpose of encouraging their passage through the gastrointestinal barrier, while controlling the release kinetics of said active ingredients.Type: GrantFiled: January 30, 2008Date of Patent: May 28, 2013Assignee: Coatex S.A.S.Inventors: Olivier Guerret, Jean-Marc Suau
-
Publication number: 20130129810Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.Type: ApplicationFiled: April 12, 2011Publication date: May 23, 2013Applicants: Tel Hashomer Medical Research Infrastructure and Services Ltd., RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Jonathan Leor, Tamar Ben-Mordechai, Shimrit Adutler-Lieber, Rimona Margalit, Inbar Elron-Gross, Yifat Glucksam-Galnoy